Clodronic Acid (Clodronate)

Subscribe to Selected New Research on Clodronic Acid

688 relevant articles (100 outcomes, 192 trials/studies) found for this Bio-Agent

Description: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.

Also Known As:

Clodronate; Bonefos; Cl2MDP; Clodronate Disodium; Clodronate Sodium; Dichloromethane Diphosphonate; Dichloromethanediphosphonate; Dichloromethanediphosphonic Acid; Dichloromethylene Biphosphonate; Dichloromethylenebisphosphonate; Acid, Clodronic; Acid, Dichloromethanediphosphonic; Biphosphonate, Dichloromethylene; Diphosphonate, Dichloromethane; Diphosphonate, Dichloromethylene; Disodium, Clodronate; Sodium, Clodronate; Dichloromethylene Diphosphonate; Phosphonic acid, (dichloromethylene)bis-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 42

Organophosphorus Compounds: 131

Diphosphonates: 3046

Clodronic Acid: 688

difluoromethylene diphosphonate: 1

difluoromethylenesulfonic acid

Experts

1.	Monteforte, P: 5 articles (10/2003 - 01/2000)
2.	Rovetta, G: 5 articles (10/2003 - 01/2000)
3.	McCloskey, Eugene: 4 articles (01/2006 - 08/2002)
4.	Elomaa, I: 4 articles (03/2005 - 01/2001)
5.	Saarto, T: 4 articles (03/2005 - 01/2001)
6.	McCloskey, E V: 3 articles (11/2007 - 06/2001)
7.	Kanis, John A: 3 articles (01/2007 - 08/2002)
8.	Powles, Trevor: 3 articles (01/2006 - 08/2002)
9.	Blomqvist, C: 3 articles (03/2005 - 01/2001)
10.	Kanis, J A: 3 articles (10/2003 - 03/2001)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 12/01/2008 - "Significant reductions in the incidence of bony and visceral metastases and improvement in duration of DFS at 36- and 55-month follow-up periods were no longer seen with clodronate. " 08/01/2002 - "The occurrence of nonosseous metastases was similar (clodronate, n = 112; placebo, n = 128; P =.257), but there was a significant reduction in mortality (clodronate, n = 98; placebo, n = 129; P =.047) during the total follow-up period. " 08/01/2002 - "During the medication period there was a significant reduction in the occurrence of bone metastases (clodronate, n = 12; placebo, n = 28; HR, 0.44; 95% CI, 0.22 to 0.86; P =.016). " 01/01/2002 - "Adjuvant clodronate was found to be associated with a significant reduction in the incidence of bone metastases during the treatment period. " 08/01/1999 - "In addition, clodronate recipients had a significantly greater incidence of nonskeletal metastases (local and visceral), and significantly lower survival rates. " Order ALL the reference details at left...
2.	Pain (Aches) 06/01/1994 - "Short term intravenous administration (usually 300 mg/day for 5 days) or longer courses of oral clodronate (usually 1600 mg/day for 6 months) effectively reduced bone pain and/or improved mobility in most patients with Paget's disease, and these effects persisted for up to 12 months after discontinuing clodronate. " 01/01/2001 - "At the end of treatment, pain relief was significantly greater in patients treated with disodium-clodronate. " 12/01/1995 - "Clodronate is also effective in some patients in reducing bone pain and improving mobility. " 09/01/1995 - "Three of 27 patients continued to have relief from pain after 3 months of oral clodronate therapy. " 01/01/1992 - "Our preliminary findings suggest that Cl2MDP is safe, and has analgesic properties that may prove to be useful in the management of metastatic bone pain." Order ALL the reference details at left...
3.	Breast Neoplasms (Breast Cancer) 08/01/1999 - "Currently, clodronate is probably most effective in the treatment and prevention of general skeletal complications in patients with breast cancer." 01/01/1992 - "Thus, clodronate seems to be a safe and highly efficacious drug for the treatment of hypercalcaemia in breast cancer patients." 01/01/2006 - "Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]." 06/01/2009 - "Furthermore, long-term follow-up of a single study in patients with bone marrow micrometastases from breast cancer revealed overall survival benefits for patients receiving clodronate 1600 mg/day compared with placebo; however, combined results from several trials of clodronate are inconclusive. " 12/01/2008 - "CONCLUSION: These long-term survival data extend the survival advantage reported in previous studies with oral clodronate in breast cancer." Order ALL the reference details at left...
4.	Hypercalcemia (Milk Alkali Syndrome) 01/01/1989 - "Chloromethanediphosphonate (Cl2MDP), a cation chelator, is used as a therapeutic for hypercalcemia of malignancy. " 09/01/1997 - "Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity." 09/01/2003 - "Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration." 07/01/2001 - "Hypercalcemia did not occur in the clodronate group but was observed in four placebo-treated patients. " 10/15/1997 - "In addition, the use of long term clodronate in patients with myelomatosis significantly decreases the progression of osteolytic bone lesions, the risk of fractures, and the incidence of hypercalcemia. " Order ALL the reference details at left...
5.	Neoplasms (Cancer) 05/01/2008 - "Overall, these results suggest that antiangiogenesis by clodronate can be used to treat a wide spectrum of angiogenesis-dependent diseases, including certain chronic inflammatory diseases and cancer." 11/01/2004 - "Moreover, our data suggest that ER is involved in these effects of clodronate on cancer cell growth." 06/01/1999 - "CONCLUSIONS: Absolute concentrations in serum and excretions in urine of orally given clodronate increase dose-dependently, but during the maintenance therapy in hospitalized cancer patients the renal drug clearances seem to be lower than in healthy volunteers. " 06/01/1999 - "During the routine cancer therapy with 400 mg thrice daily, the clodronate excretions in urine on two successive days were on an average 3.26% (range 0.0-10.5%). " 06/01/1996 - "These results indicate that clodronate treatment decreased bone turnover and attenuated cancer-related bone morbidity. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Clodronic Acid (Clodronate)
2.	pamidronate (APD)
3.	Liposomes (Liposome)
4.	zoledronic acid (zoledronate)
5.	Diphosphonates
6.	Calcium
7.	Etidronic Acid (HEDP)
8.	ibandronic acid (Boniva)
9.	Calcitonin (Calcitonin, Eel)
10.	collagen type I trimeric cross-linked peptide

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intramuscular Injections
3.	Ovariectomy (Oophorectomy)
4.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
5.	Intravenous Injections

Best Treatments:
Research Summary Report
on Neoplasm Metastasis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3261 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>